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NAb screening, and no therapy) were included in the model.
Data from pivotal clinical trials, US product labeling, and other
published sources were used to estimate disease progression,
relapse rates, treatment efﬁcacy (reductions in relative risk of
progression/relapse; effect of NAbs on efﬁcacy), adverse events,
therapy discontinuation/switching, costs, and patient utilities.
For each treatment scenario, incremental cost per QALY was
assessed relative to no therapy, and each screening scenario 
was compared to its corresponding “no screening” scenario.
RESULTS: Incremental cost per QALY (lifetime treatment; 3%
discounting) ranged from $75,300 (Avonex) to $135,900
(Betaseron). NAb screening resulted in 10-year cost savings of
US$5100 per patient (Rebif) and US$3000 (Betaseron), versus
US$800 additional cost for Avonex. CONCLUSIONS: Based on
higher occurrence of NAbs with Betaseron and Rebif, universal
NAb screening of patients treated with these agents improves
clinical effectiveness and is cost saving. However, NAb screen-
ing for Avonex-treated patients is cost additive due to Avonex’s
lower immunogenicity.
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HEALTH CARE COSTS FOR FLORIDA MEDICAID RECIPIENTS
WITH MULTIPLE SCLEROSIS
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OBJECTIVE: To assess health care costs among patients with
multiple sclerosis (MS) in the Florida Medicaid program.
METHODS: We employed a retrospective matched cohort
design using administrative claims data for Florida Medicaid
recipients. Patients were included if they had a diagnosis of MS
between July 1, 2001 and June 30, 2002, and were eligible for
Medicaid as of July 1, 2001. Those covered in capitated plans
or dually eligible for Medicare and Medicaid were excluded. The
comparison cohort consisted of MS-free patients matched on
age, gender, and race to the MS group. The excess cost of MS
(in 2002 US dollars) was estimated as the difference in mean
Medicaid payments between the MS group and matched con-
trols. Patients were followed for 12 months unless eligibility ter-
minated earlier. RESULTS: A total of 951 patients with MS met
cohort selection criteria, a prevalence rate of approximately 8
per 10,000 Medicaid eligibles. About one-third of these patients
were dispensed glatiramer acetate or beta-interferon. MS
patients and matched controls (n = 951) averaged 43 years of
age; 78% were female, and 61% were white. Both cohorts had
similar mean Charlson comorbidity scores and low mortality
rates (<3%). Compared to their matched controls, MS patients
were more likely to be hospitalized (33% vs. 20%, respectively),
use nursing home services (15% vs. 3%), or use home health
care services (37% vs. 11%). The annual per-patient excess cost
of MS was estimated to be $11,383 ($20,264 vs. $8,881 for
matched controls). Long-term care accounted for 44% of the
excess costs, followed by medications (28%), and hospitaliza-
tions (14%). CONCLUSIONS: Although MS is relatively rare in
this Medicaid population, the per-patient costs are high. Long-
term care costs are the largest portion of Medicaid payments,
highlighting the disease burden.
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OBJECTIVES: Interferon beta-1a (Avonex®) is efﬁcacious in
delaying clinically deﬁnite multiple sclerosis (CDMS) following
a single demyelinating event (SDE). This study determined the
cost-utility of Avonex® compared to current treatment (CT) in
delaying the onset of CDMS. METHODS: A cost utility analy-
sis (CUA) was performed. The outcome of interest was the
quality adjusted time spent in the pre-CDMS state, termed
quality adjusted monosymptomatic life years (QAMLYs) gained.
A Markov model was developed with all transitional probabili-
ties and utilities derived from the literature. Costs were reported
in 2002 Canadian dollars. Costs and outcomes were discounted
at 5%. A time horizon of 15 years was applied. All uncertain-
ties were tested via univariate and multivariate sensitivity analy-
ses. RESULTS: From the Ministry of Health (MoH) perspective,
the total expected costs per patient over 15 years were $202,000
and $136,000 for Avonex® and CT, respectively. From the soci-
etal perspective, the total expected costs were $380,000 and
$327,000, respectively. Expected QAMLYs gained were 8.47 for
Avonex® and 8.18 for CT. The incremental cost of Avonex® per
QAMLY gained was $227,586 from the MoH perspective and
$189,286 from the societal perspective. The model was sensitive
to the probability of progressing to CDMS, the utilities, and the
analytical time horizon. CONCLUSION: This analysis demon-
strates an improvement in the cost utility of Avonex® compared
to a previously published CUA for CDMS, providing further evi-
dence of the beneﬁts of treatment following a SDE.
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OBJECTIVE: To compare the average direct costs for patients
diagnosed with vascular dementia (VaD) versus Alzheimer’s
disease (AD) from the perspective of the Taiwan National Health
Insurance (NHI) program. METHODS: Using health care claims
data for NHI recipients in the Bureau of National Health Insur-
ance Kao-Ping Branch, Taiwan, we evaluated NHI expenditures
among adults 50 + years of age diagnosed with VaD (ICD-9-CM
290.4X) or AD (ICD-9-CM 331.0) between July 1, 2000 and
December 31, 2002. Patient’s identiﬁcation period spanned from
Jan 1, 2001 through Dec 31, 2002 with a 6-month baseline
periods and 1-year follow up period. Direct costs estimated using
NHI physician fee schedules. Health care utilization and NHI
expenditures (in 2002 NHI reimbursement prices) were calcu-
lated overall and by component of care. Multivariate techniques,
based on regression analyses of the log of total costs, were
employed to adjust for differences between the study cohorts in
sociodemographics. RESULTS: In total, 1450 patients met study
inclusion criteria; Of the 710 were diagnosed with VaD, 41.6%
were women; Of the 740 with AD, 50.7% were women. The
average age for VaD was 76.25 years and 76.79 years for AD.
Relative to AD patients, the burden of comorbidity was higher
among VaD patients, especially for cerebrovascular disease
(43.2% vs. 15.9%), but also for diabetes (5.6% vs. 3.1%) and
chronic pulmonary disease (5.5% vs. 1.4%). Mean monthly
costs per patient were approximately NT$1013 higher for
patients with VaD versus AD (NT$5467 vs. 4454; p < 0.001).
Most of this excess cost were attributed to higher inpatient uti-
lization (84.8%) and mental health services (11.2%). Adjusting
for difference in age, gender, and comorbid conditions between
the two cohorts, mean monthly cost per patient were about
NT$1107 higher in the VaD cohort (NT$3892 vs. 2785; p <
0.001). CONCLUSIONS: Relative to AD patients, VaD have sig-
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niﬁcantly higher health care costs. Efforts to better control
comorbid diseases such as cerebrovascular risk factors may
decrease the future burden of VaD.
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OBJECTIVE: Parkinson’s disease (PD), a progressive neurologi-
cal disorder, affects approximately 1% of the population over 65
in the United States. Average annual Medicaid costs per patient
for all patients were $3759 in 1998. The overall economic
burden of PD was estimated at $25 billion annually in 1997.
This study quantiﬁes direct medical care costs for individual
Medicaid beneﬁciaries with PD. METHODS: Patients with at
least 12 months of continuous enrollment in Medstat’s 
MarketScan® Multi-state Medicaid claims database were iden-
tiﬁed. Patients were required to have either two claims with a
diagnosis of PD (ICD-9-CM 332.0) or one diagnosis and two or
more prescriptions for a PD-related medication (levodopa/
carbidopa, dopamine agonist, MAO-B inhibitor, or COMT
inhibitor). Health care utilization and expenditures accrued from
the ﬁrst observed diagnosis or prescription. Because patients
were allowed to have varying lengths of follow-up (minimum:
12 months), expenditure and utilization data were annualized.
RESULTS: A total of 11,882 patients with PD were identiﬁed
and followed for an average of 821 days. The mean age of the
sample was 73.9 years and 57.6% were women. Mean total
annual health care expenditures were $18,586 (SD $25,592) per
patient. Nineteen percent had at least one hospital admission
while long term care was utilized by 15.8% of patients. Average
annual inpatient hospitalization costs were $8921 (SD $1559),
while long term nursing home care expenditures accounted for
$31,434 (SD $27,659). In addition to PD-speciﬁc care, 16.9%
were diagnosed with a fall or injury and 8.2% with dementia,
while 44.4% were treated with antidepressants and 31.1% were
treated with antipsychotic medications. CONCLUSION: Mean
total health care expenditures for Medicaid patients with PD
were nearly ﬁve times the average Medicaid costs previously
reported for elderly beneﬁciaries. Further investigation of the
burden of PD will entail comparisons to a matched cohort of
Medicaid patients without PD.
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OBJECTIVES: To determine the costs, effects, and cost-
effectiveness of the treatment of Traumatic Brain Injury (TBI)
with calcium channel blockers vs. standard care. METHODS: A
Monte Carlo model of acute TBI was constructed from the
payer’s perspective and used to compare the costs and effects 
of treatment with calcium channel blockers to standard care. 
The intervention modeled was the calcium channel blocker
Nimodipine intravenously, 1mg/hr the for ﬁrst 2 hours and 2
mg/hr thereafter for up to 7 days to control intracranial pressure
(ICP). Standard care is no drug intervention to control ICP. The
outcomes of the model were good recovery, severe disability or
persistent vegetative state (PVS), and death. Outcome probabil-
ities were derived from the literature. Average treatment costs of
TBI were derived from the literature. Modeling and sensitivity
analysis were performed using Data 4.0. The incremental cost,
incremental effectiveness, and incremental cost-effectiveness
were tested using SPSS 11. RESULTS: The incremental cost of
treating TBI with a calcium channel blocker was $15,469 above
standard care (p < 0.001). The incremental effectiveness of treat-
ing TBI was 0.02 Quality Adjusted Life Years (QALY) more than
standard care (p < 0.001). The incremental cost-effectiveness of
treating TBI was $24,030 per QALY (p < 0.001). CONCLU-
SIONS: The incremental cost of treating TBI with a calcium
channel blocker of $15,469 is signiﬁcant, but it is not unrea-
sonable. Considering the severity of the TBI and the importance
that even a small reduction in mortality and disability would
have, the incremental cost of treating TBI with a calcium channel
blocker should not be considered an obstacle to treatment.
NEUROLOGICAL/GENETIC DISORDERS (Migraine,
Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter
Syndrome, Insomnia)
NEUROLOGICAL/GENETIC DISORDERS (Migraine,
Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter
Syndrome, Insomnia)—Quality of Life Studies
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OBJECTIVE: Epilepsy affects up to 1% of the population. With
advances in treatment, up to 90% of epileptics have reasonably
controlled seizures. This has not translated into parity in the
workplace and up to 25% of epileptics remain unemployed. In
this study, we determine those variables that distinguish epilep-
tics who work from those who do not. METHOD: Seventy
patients aged 18–65 years with conﬁrmed epilepsy who did not
undergo epilepsy surgery or vagal nerve stimulator implantation
was randomly selected from our epilepsy database. A 36-item
multiple-choice questionnaire that focused on demographic,
disease-related and employment-related information was sent.
Patients were categorized as being full-time employed, part-time
employed or unemployed. Using a Fischer exact test at a 90%
level of conﬁdence, we identiﬁed those variables that distin-
guished epileptics who were 1) employed (full-time and part-
time) from those who were unemployed, and 2) full-time
employed from non-fulltime employed. RESULTS: Nineteen
questionnaires were returned Patients’ ages ranged from 21 to
59 years and 63% were females. Twenty-six percent were
married and 68% were Caucasians. Thirty-three percent were
employed full-time and 61% were unemployed. Variables that
distinguished epileptics who were employed (either fulltime or
part time) were perceived higher intelligence (p = 0.0429), the
absence of disability beneﬁts (p = 0.0152), shorter history of
seizures (p = 0.0338), and perceived importance of work for both
personal (p = 0.0498) and ﬁnancial (p = 0.0498) reasons. Vari-
ables that distinguished epileptics who were fully employed were
perceived higher intelligence (p = 0.0245), the absence of dis-
ability beneﬁts (p = 0.0498) and perceived importance of work
for personal reasons (p = 0.0537). CONCLUSION: Employment
among epileptics correlates with perceived intelligence, the
absence of disability beneﬁts, the duration of epilepsy and per-
ceived importance of work. Most disease-related variables do not
signiﬁcantly inﬂuence employability. Integrating work-directed
programs into the routine care of epileptics may decrease the
level of unemployment in this population.
